Elekta pioneers modern cancer care through R&D leadership

More than 13 million new cancer cases occur globally every year, of which 3
million are in Europe, according to the World Health Organization. And as the
population ages, the number of cancer cases is expected to rise. Through patient
-focused research and development initiatives, Elekta’s goal is to make
treatment more available and promising for these people. Elekta’s President and
CEO, Tomas Puusepp, recently described how patients benefit through the
company’s growth and R&D leadership.

Speaking at a Capital Markets Day, in conjunction with the 2012 European Society
for Therapeutic Radiology and Oncology (ESTRO) exhibition, Tomas Puusepp said
Elekta’s portfolio of leading-edge integrated solutions and services mean more
people can be treated. “Every year, about 1 million patients benefit from
treatment with an Elekta solution,” he said. “And our commitment to expansion
and innovation is expected to give many more patients access to first-rate and
affordable cancer care. Each year we invest 8-9% of our net sales in R&D with
the aim of improving outcomes through the best clinical solutions on the market.
This is how we pioneer modern cancer care.”

Dee Mathieson, Senior Vice President, Oncology Business Line Management, said:
“Elekta is working with leading clinicians to address the challenge of improving
treatment of some of the major cancers, such as lung, breast and prostate
cancers. Through ongoing collaboration with our research groups, we create
solutions that advance clinical outcomes. Our latest solution, Agility*™, is a
great example of this.”

Agility is Elekta’s revolutionary multileaf collimator (MLC) that further
enhances high-precision beam shaping around the tumor; features low leakage to
minimize dose delivery to healthy tissue; and shortens treatment times. Elekta
has collaborated closely with leading hospitals and research institutions to
develop this solution, which can increase the throughput of patients while
delivering outstanding precision.

Clarity®is another example of Elekta’s innovative solutions. Clarity takes soft
tissue visualization to entirely new levels, using ultrasound images to
accurately identify soft tissue structures during planning and treatment. It is
an affordable and ideal platform for motion management, increasing the
clinician’s confidence.

“Elekta has a clear strategy to develop complete and leading-edge solutions with
patient care in focus,” Puusepp said. “This is part of Elekta’s evolution in
cancer care and will grow our company while delivering clinical benefits and
positive patient outcomes.”

Elekta showcased its portfolio at ESTRO (May 9-13) through the ‘Elekta Cancer
Care Clinic’, a simulated reception, pre-treatment and simulation rooms,
doctor’s office, treatment planning and physics rooms, and a treatment delivery
suite. This “clinic” allowed Elekta to demonstrate the breadth and scope of its
comprehensive, integrated offerings.

For questions, please contact:

Stina Thorman, Vice President Corporate Communications, Elekta AB (publ)
+46 8 587 25 437, stina.thorman@elekta.com

Johan Andersson Melbi, Investor Relations Manager, Elekta AB (publ)
+46 702 100 451, johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 15.15 CET on May 10, 2012.

*Not for sale or distribution in all markets depending on status of approval and
clearances

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,300 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb.